ARCH Venture Partners — Full Portfolio

908 Devices manufactures handheld mass spectrometry and chemical analysis devices for rapid detection in defense, security, and hazardous materials response applications.

Deep TechDefense TechHardwareMedical DevicesBoston, US

KJKevin J. Knopp, PhD(CEO & Co-founder)CBChristopher Brown(Executive Officer)inKKKevin Knopp(Executive Officer, Director)inJoseph Griffith IV(Executive Officer)

BoardCorey Steffek(Director)

Board seatKCKeith CrandellKHKevin Hrusovsky· per SEC Form D

Co-investorsRARazor's Edge VenturesUTUTECARAramco VenturesARARK Investment ManagementBLBlackRockNONorthpond Ventures

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.

BiotechDeep TechMedical DevicesCambridge, US

DRDavid R. Liu(Founder and Inventor)inJKJ. Keith Joung(Founder and Inventor)inFZFeng Zhang(Founder and Inventor)DRDavid R. Liu, Ph.D.(Founder and Inventor)JKJ. Keith Joung, M.D., Ph.D.(Founder and Inventor)FZFeng Zhang, Ph.D.(Founder and Inventor)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsDRDreamers VCEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalGVGV (Google Ventures)HOHongShan Capital Group+1 more

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)

Board seatKBKristina Burow· per SEC Form D

Co-investorsNENextech InvestRARA CapitalNENEXTECH ONCOLOGY SCSPSISignalFire

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Board seatRHRichard Heyman· per SEC Form D · $90M raise · filed Apr 2024

Co-investors5A5AM VenturesOROrbiMedPFPfizer Venture InvestmentsRORoche Venture FundBABay City CapitalNENew Enterprise Associates (NEA)+1 more

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

BiotechDigital HealthMedical DevicesSan Diego, US

FHFaheem Hasnain(Executive Officer, Director)inChristian Waage(Executive Officer)inSGSheila Gujrathi, MD(Founder)inBGBryan Giraudo(Executive Officer)Laura Carter, Ph.D.(Executive Officer)Robert Smith(Executive Officer)

Board seatKBKristina BurowRNRobert Nelsen· per SEC Form D

Co-investorsBABay City CapitalECEcoR1 CapitalFOFoothill VenturesNENew Enterprise Associates (NEA)SASamsara BioCapitalOMOmega Funds

GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Jeffrey T. Huber(Director)JOJoshua Ofman, MD, MSHS(Chief Executive Officer)inAFAaron Freidin(Executive Officer)inJOJosh Ofman(Executive Officer)inRobert Ragusa(Executive Officer, Director)JCJennifer Cook(Executive Officer, Director)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsAMAmino CapitalBEBezos ExpeditionsBLBluebird VenturesDEDecheng CapitalDEDentsu VenturesFEFelicis Ventures+8 more

Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.

BiotechDeep TechDigital HealthMedical DevicesWatertown, US

PLPaul L. Berns(Chairman and Chief Executive Officer)Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)inKari Stefansson(Director)MHMaykin Ho(Director)AHAlaa Halawa(Director)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsCACatalio Capital Management, LPF-F-Prime CapitalK2K2 HealthVenturesMEMercury FundPRPremier PartnersSOSoftBank Vision Fund+3 more

Quanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention.

BiotechDigital HealthHealthtechMedical DevicesLexington, US

DWDavid Walt(Director)inErnest Orticerio(Executive Officer)Ernest Oriticerio(Executive Officer)MTMasoud Toloue(Former Chief Executive Officer)in

BoardJohn Connolly(Director)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsFOFoothill VenturesKHKhosla VenturesNONovalis LifeSciences

Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.

BiotechCambridge, US

NMNagesh Mahanthappa(Executive Officer, Director)inTSTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAVAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVSVikas Sinha(Chief Financial Officer)in

Board seatKBKristina Burow· per SEC Form D

Co-investorsAIAisling CapitalECEcoR1 CapitalARARCH VenturePOPolaris Partners

Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.

BiotechCambridge, US

Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in

Board seatKBKristina Burow· per SEC Form D · $47M raise · filed Jan 2018

Co-investorsSASamsara BioCapitalARARCH VentureECEcoR1 CapitalPOPolaris Partners

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO and Board Member)inMCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)inEGEric Green(Executive Officer)in

BoardJIJames I. Healy(Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsFOForesite CapitalHAHAWKTAILPUPureTech HealthSOSofinnova VenturesTHThird Rock Ventures

Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.

BiotechDeep TechSemiconductorsSouth San Francisco, US

William Charles Banyai(Executive Officer, Director, Promoter)BJBill James Peck(Executive Officer, Promoter)ELEmily Leproust(Founder)inEMEmily M. Leproust(Chief Executive Officer and Chair of the Board)inPFPatrick Finn(President and Chief Operating Officer)inALAdam Laponis(Chief Financial Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investors+N+ND Capital3E3E Bioventures CapitalASAsset Management CompanyBABay City CapitalBLBlack Opal VenturesDEDentsu Ventures+8 more

Vir Biotechnology develops treatments for infectious diseases and oncology, leveraging immunology-focused scientific capabilities.

AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US

MDMarianne De Backer(CEO)inHerbert Virgin(Executive Officer)Howard Horn(Executive Officer)inABAlex Bangs(Executive Officer)in

BoardGSGeorge Scangos(Executive Officer, Director)

Board seatRNRobert NelsenKBKristina BurowVSVicki Sato· per SEC Form D

Co-investorsALAlta PartnersSOSoftBank Vision Fund8V8VCSOSoftBank Group

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases of the central nervous system, including Alzheimer's disease, ALS, and Parkinson's disease.

BiotechHealthtechLexington, US

TCTodd Carter(Executive Officer)inRobin Swartz(Executive Officer)inASAlfred Sandrock(Executive Officer, Director)PPPeter Pfreundschuh(Executive Officer)inNathan Jorgensen(Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer)Steven Hyman(Director)

Board seatGSGeorge Scangos· per SEC Form D · $20M raise · filed Jan 2024

Co-investorsFIFidelity InvestmentsTHThird Rock Ventures

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.

BiotechHealthtechMedical Devices

Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)CBCraig B. Thompson, M.D.(Founder)BGBrian Goff(Chief Executive Officer)in

Co-investorsTHThird Rock VenturesFLFlagship VenturesSASamsara BioCapital

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

JMJohn Maraganore(Founder)inDYDr. Yvonne Greenstreet(Chief Executive Officer)inJeffrey V. Poulton(Executive Vice President and Chief Financial Officer)BABryan A. Supran(Executive Vice President, Chief Legal Officer and Secretary)inPGPushkal Garg(Executive Vice President and Chief Research and Development Officer)inTTTolga Tanguler(Chief Commercial Officer)in

Co-investorsATAtlas VentureBLBlackstone Life SciencesCACardinal PartnersINInvivo Capital Partners

Denali Therapeutics develops therapeutics for neurodegenerative diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

MTMarc Tessier-Lavigne(Director)inRyan Watts(Executive Officer, Director)inAOAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSESteve E. Krognes(Director)in

Co-investorsECEcoR1 CapitalF-F-Prime CapitalFOForesite CapitalARARCH VentureFLFlagship PioneeringFLFlagship Ventures+1 more

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in

BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)

PartnerKBKristina Burow· quoted

Co-investorsANAndreessen HorowitzEVEvolution VC PartnersFRFrazier Life SciencesCICity Hill VenturesCOColt VenturesLILifeSci Venture Partners+1 more

Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.

AI & Machine LearningBiotechDeep TechSomerville, US

GGGevorg Grigoryan(Co-Founder & Chief Technology Officer)in

Co-investorsFLFlagship PioneeringMAMarch Capital PartnersALAlaska Permanent Fund CorporationALALTITUDE LIFE SCIENCE VENTURESNVNVenturesT.T. Rowe Price

Kardigan develops targeted cardiovascular treatments through a discovery and translational research platform, with a pipeline of late-stage drug candidates aimed at functional cures for cardiovascular disease.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsCACatalio Capital Management, LPT.T. Rowe Price

Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.

BiotechDigital HealthMedical DevicesLa Jolla, US

TWTROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYLYI LIU(Executive Officer)inTWTroy Wilson(Founder)inTETroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsECEcoR1 CapitalFOForesite CapitalNENextech InvestOUOUP (Osage University Partners)ARARCH Venture

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)FRFrazier Healthcare PartnersJAJanus Henderson Investors+3 more

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsCACatalio Capital Management, LPFOForesite CapitalFRFrazier Life SciencesGEGeneral CatalystNENextech InvestRARA Capital+7 more

PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.

BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US

Richard Scott PerkinJames M. Mock(Executive Officer)AOAndrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)PSPrahlad Singh(Executive Officer, Director)inTajinder Vohra(Executive Officer)in

Co-investorsAMAmpersandPAPartners for GrowthPAPartners for Growth (PFG)

Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.

BiotechDeep TechHealthtechMedical DevicesFramingham, US

Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim CEO; Interim CFO)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)

BoardRichard Conley(Director)

Co-investors5A5AM VenturesALALTITUDE LIFE SCIENCE VENTURESPOPolaris Partners

Rapport is a biopharmaceutical company developing novel therapeutics.

BiotechHealthtechMedical Devices

ACAbe Ceesay(President)CGCheryl GaultinDr. SevignyAbraham N. Ceesay(President and Chief Executive Officer and Director)

Co-investorsSOSofinnova VenturesCACapital GroupJOJohnson & Johnson Innovation – JJDCTHThird Rock Ventures

Basking Biosciences develops therapeutics for thrombosis, vascular biology, and ischemic disease.

BiotechDigital HealthHealthtechMedical DevicesCary, US

SNShahid Nimjee(Co-founder, Chief Scientific Officer and Stroke Clinical Lead)inBruce Sullenger(Co-founder)JOJulia Owens(Executive Officer, Director, Promoter)inRSRichard Shea(Executive Officer, Director, Promoter)in

BoardHannah Chang(Director)AAAiden Aceves(Director)in

Board seatSGSteve Gillis· per SEC Form D

Co-investorsINInsight PartnersBRBroadview VenturesSOSolas BioVenturesRERev1 VenturesRTRTW Investments L.P.

Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.

BiotechHealthtechMedical DevicesWoburn, US

Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)DDDenise Dajles, PhD(President & CEO)JMJohn McDonough(Executive Officer, Director)inDSDavid Stone(Executive Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsSASands Capital Ventures

IngredientWerks is a molecular farming company that engineers plants to produce plant-based proteins and ingredients for the alternative protein market.

AgTechBiotechFoodTechWoburn, US

MPMatt Plavan(Chief Executive Officer)inMichael Raab(R&D Lead)JSJeremy Schley-Johnson(Vice President)inSteve Snyder(Director)James Schultz(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsOPOpen PrairieCUCultivian Sandbox VenturesSASandbox Industries

Vizgen develops high-throughput spatial profiling technologies, including MERFISH-based spatial genomics and spatial proteomics tools for life science research and precision oncology.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesCambridge, US

GEGeorge Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inXZXiaowei Zhuang(Founder; Professor, Harvard University)inFenel Eloi(Director)RCRob Carson(Chief Executive Officer)inSimona Levi(Chief Legal Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsNONorthpond Ventures6 6 Dimensions CapitalALAlly Bridge GroupAPApplied VenturesKIKilonova CapitalPUPura Vida Investments+3 more

Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

GEGeorge Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)TLTerry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsM M VenturesNONorthpond VenturesILIllumina VenturesNONovalis LifeSciences

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.

AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US

FZFeng Zhang, Ph.D.(Scientific Founder & Board Observer)AAAkin Akinc, Ph.D.(Chief Executive Officer & Board Director)

Co-investorsLULux CapitalF-F-Prime CapitalGVGV (Google Ventures)JDJDRF T1D FundNENewpath Partners

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDMDamien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)ANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)

Co-investorsLILifeforce CapitalOROrbiMedDODomain AssociatesEDEDB InvestmentsSESection 32FRFrazier Life Sciences+4 more

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.

AI & Machine LearningBiotechDeep TechBoston, US

RYRichard Young, Ph.D.(Director)AHAnthony Hyman, Ph.D.(Director)THTony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inANAmeet Nathwani, M.D.(Executive Officer, Director)in

Co-investorsECEcoR1 CapitalSASamsara BioCapital6 6 Dimensions CapitalGEGeneral CatalystINInnovation EndeavorsLELeaps by Bayer+5 more

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtechBurlington, MA, US

AOArthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)Arthur Tzianabos, Ph.D.(President & Chief Executive Officer)Jay Rothstein, Ph.D.(Scientific Co-Founder and Advisor)

Co-investorsATAtlas VentureSASanofi Ventures5A5AM Ventures

Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.

AI & Machine LearningBiotechMedical DevicesBoston, US

Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)MRMichael Rosbash, PhD(Founder & Advisor)RSRicha Saxena, PhD(Founder & Advisor)SSStuart Schreiber, PhD(Founder & Advisor)BSBrian Safina(President & Chief Executive Officer)in

Co-investorsNENewpath PartnersTATaiho Ventures, LLC

Moleculent develops biological discovery and disease understanding tools for scientists.

AI & Machine LearningBiotechDeep Tech

FRFredrik Roos(CTO & Co-founder)in

Co-investorsEIEIR Ventures

Paradigm Health operates a platform that increases patient access to clinical trials through a provider-facing infrastructure combined with AI-powered research technology.

AI & Machine LearningHealthtechMedical DevicesSaaSColumbus, US

KTKent Thoelke(Founder and Chief Executive Officer)inJonathan Hirsch(Chief Strategy and Growth Officer)

Co-investorsGEGeneral CatalystLULux CapitalF-F-Prime CapitalGVGV (Google Ventures)MAMagnetic VenturesMUMubadala Capital

Paradigm Health provides technology and services that integrate with healthcare provider organizations to improve the clinical trial process.

BiotechDigital HealthHealthtech

KTKent Thoelke(Founder & CEO)inJonathan Hirsch(Chief Strategy and Growth Officer)JTJay Trepanier(Chief Financial Officer)inElijah Meerson(Chief Technology Officer)inMLMichelle Lee(Chief Operating Officer)in

Co-investorsGEGeneral CatalystGVGV (Google Ventures)LULux CapitalJOJobsOhio Ventures

Pelage develops regenerative medicines for hair loss based on stem cell biology, with a lead candidate (PP405) that is a topical small-molecule drug designed to reactivate dormant hair follicle stem cells.

BiotechHealthtechLongevity

WLWilliam Lowry(PhD)inCWChristina Weng(Chief Medical Officer)inNWNathan Wheeler(Chief Operating Officer)in

BoardDGDaniel Gil(PhD)

Co-investorsGVGV (Google Ventures)HAHAWKTAILVIVisionary VenturesYKYK Bioventures

Pretzel Therapeutics develops therapeutics targeting bioenergetic dysfunction and mitochondrial disease by addressing defects in mitochondrial DNA function and gene expression.

BiotechDeep TechHealthtechMedical Devices

MMMichal Minczuk(Co-Founder)inGMGabriel Martinez(Chief Scientific Officer & Co-Founder)CGClaes Gustafsson(Co-Founder)MFMaria Falkenberg(Co-Founder)NLNils-Göran Larsson(Co-Founder)Gabriel Martinez, Ph.D.(Chief Scientific Officer & Co-Founder)

Co-investorsCACambridge Innovation CapitalEIEIR VenturesANAngelini VenturesGVGV (Google Ventures)HEHealthCap

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

BRBotond Roska(Researcher (M.D., Ph.D.))BGBence György(IOB Assistant Professor & Head of Clinical Translation)inKHKatherine High(CEO)in

Co-investorsNONovartis Venture FundBIBioGeneration VenturesF-F-Prime CapitalGVGV (Google Ventures)

Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.

BiotechMedical Devices

TETony Estrada(President & Chief Executive Officer)in

Co-investorsF-F-Prime Capital

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

TSThorsten Stafforst(Chairman of the Board of Directors)inKEKris ElveruminTBTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+N+ND CapitalFOForbionVEVenrockFAFast Track InitiativeNENextech InvestNONovalis LifeSciences+2 more

Fabless US semiconductor company making ultralow-power non-volatile memory, ASICs and IoT embedded systems; acquired by Dialog in 2020.

Sunnyvale, US

NDNarbeh Derhacobian(Executive Officer, Director)inRon Shelton(Executive Officer)in

BoardMatt Boyle(Director)AAAlexei Andreev(Director)inBarry Cox(Director)

Board seatKCKeith Crandell· per SEC Form D · $12.5M raise · filed Sep 2015

US agricultural biotech that discovered microbe-based crop protection products; its assets were sold to Certis Biologicals and Ginkgo Bioworks in 2024.

AgTechResearch Triangle Park, US

Scott Uknes(Manager)inEWEric Ward(Manager)PSPaul Schulze-Lefert(President)Michael Koziel(Vice President and Manager)

BoardThomas Dietz(Manager)

Board seatKBKristina Burow· per SEC Form D · $34.5M raise · filed Aug 2015

Co-investorsALAliment CapitalBLBlue Horizon CorporationPOPontifax AgTechNONovalis LifeSciencesPOPolaris Partners

Agrivida develops enzyme technology for animal feed and nutrition, improving efficiency in poultry, swine, and other livestock production.

AgTechBiotechFoodTechMassachusetts, US

RMR. Michael Raab(Executive Officer)Daniel Meagher(Executive Officer, Director)JSJeremy Schley Johnson(Executive Officer)

BoardRob Johnson(Director)Mark Austin(Director)Robert Bucklin(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsMIMiddleland CapitalPRPresidio VenturesCUCultivian Sandbox Ventures

Alzheon is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for Alzheimer's disease and other neurodegenerative disorders, with a Phase 3 program for its lead compound valiltramiprosate (ALZ-801).

BiotechDeep TechHealthtechFramingham, US

MTMartin Tolar, M.D., Ph.D.(President and Chief Executive Officer)MTMartin Tolar(Executive Officer, Director)inMTMartin Tolar, MD, PhD(Founder)inGEGlenn E. Pauly(Chief Commercial Officer)inSASusan Abushakra, M.D.(Chief Medical Officer)inJHJohn Hey, Ph.D.(Chief Scientific Officer)

Board seatScott Minick· per SEC Form D · filed Feb 2015

Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.

BiotechDigital HealthMedical DevicesCambridge, US

DADAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FZFENG ZHANG(Director)ANNIE HAZLEHURST(Director)

BoardDAVID R. WALT(Director)in

Board seatKCKeith Crandell· per SEC Form D

Co-investorsILIllumina VenturesONOno Venture Investment, Inc.TCTCG CrossoverALAlly Bridge GroupJAJanus Henderson InvestorsSESection 32+3 more

Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.

BiotechChapel Hill, US

RWRobin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Executive Officer, Director)in

BoardBenjamin Gomez(Director)AKAdam Koppel(Director)inMichael E. Bozik(Director)

Board seatPBPaul Berns· per SEC Form D

Co-investorsBABain Capital Life SciencesGVGV (Google Ventures)ACAccess BiotechnologyMAMaverick CapitalSASaturn PartnersVIViking Global Investors

Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.

HealthtechSeattle, US

Nathan Price(Director)Clayton Lewis(Executive Officer, Director)

BoardTim Kilgallon(Director)

Board seatRNRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017

Co-investorsCOCorewell Health Ventures

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

KFKevin Finney(Chairman, President and CEO)inJBJohn Borkholder(Executive Officer)in

BoardTCThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Board seatKBKristina Burow· per SEC Form D

Co-investorsCACanaan PartnersMOMonograph Capital PartnersPFPfizer Venture InvestmentsSASamsara BioCapitalNENewpath Partners

Cooledge designs and manufactures specialized lighting solutions including LED luminaires, tunable white products, and architectural lighting systems for commercial and industrial applications.

Advanced ManufacturingCleantechConstruction TechHardwareRichmond, US

BillCalvin Wade Sheen(Executive Officer, Director)

BoardWilliam Sims(Director)Kirk A. Washington(Director)GCGeoff Catherwood(Director)inThomas Bilbrough(Director)

Board seatCBClinton Bybee· per SEC Form D · $9.1M raise · filed Jan 2016

Co-investorsYAYaletown PartnersBDBDC Venture Capital

Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.

BiotechBrookline, US

Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)

BoardGMGeorge M. Church(Director)

Board seatSteven Gillis· per SEC Form D

Co-investorsALAlta PartnersCACatalio Capital Management, LPKHKhosla VenturesOUOUP (Osage University Partners)B2b2ventureKEKendall Capital Partners+1 more

Elephas develops elive, a live-tissue platform technology that predicts immunotherapy response in cancer patients by measuring real-time immune activity in intact tumor tissue.

BiotechDigital HealthHealthtechMedical DevicesMadison, US

Jonathan Oliner(Executive Officer)inMAManeesh Arora(Founder)inMichelle B. Arora(Director)Terrence P. Brady(Executive Officer)

Board seatPBPaul Berns· per SEC Form D

Co-investorsNONorthpond VenturesSASands Capital Ventures

Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.

BiotechSeattle, US

MRMark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)SHStephen Hill(Executive Officer, Director)

BoardPHPaulina Hill(Director)

Board seatSteven Gillis· per SEC Form D

Co-investorsOUOUP (Osage University Partners)POPolaris Partners

insitro is a drug discovery and development company that uses machine learning and cellular data to identify therapeutic insights and accelerate the creation of new medicines.

AI & Machine LearningBiotechSouth San Francisco, US

DKDaphne Koller(CEO & Founder)inDVDuane Valz(General Counsel)inMRMary Rozenman(Chief Financial Officer)in

BoardVPVijay Pande(Director)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsANAndreessen HorowitzFOForesite CapitalGVGV (Google Ventures)HOHOF CapitalSOSoftBank Vision FundALAlexandria+7 more

Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.

HardwareHealthtechMedical DevicesNew MaterialsAspen, US

MJMark Joseph(Founder / Inventor & Product Designer)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)

Board seatRNRobert Nelsen· per SEC Form D · $15M raise · filed Jun 2021

Co-investorsDEDecheng CapitalRSRsquared

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardANAmir Nashat(Director)in

Board seatKBKristina BurowRHRichard Heyman· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsAGage1ECEcoR1 CapitalLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)VIVivo Capital+3 more

Metsera was a clinical-stage biotechnology company developing injectable and oral medicines for obesity and metabolic diseases, including next-generation GLP-1 and amylin-based therapies.

BiotechHealthtechMedical DevicesNew York, US

CAClive A. Meanwell(Director)Christopher J. Visioli(Executive Officer)inBrian Hubbard(Executive Officer)inChristopher Whitten Bernard(Executive Officer, Director)Steven Marso(Executive Officer)

Board seatKBKristina BurowPBPaul Berns· per SEC Form D

Co-investorsALAlpha Wave GlobalF-F-Prime CapitalGVGV (Google Ventures)RARA CapitalSOSoftBank Vision FundNENewpath Partners

Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach.

AI & Machine LearningHealthtechMedical DevicesSan Diego, US

MCMark C. McKenna(Executive Officer, Director)inJoseph Papa(Director)Scott Glenn(Director)Vika Brough(Executive Officer)Timothy K. Andrews(Executive Officer)

Board seatKBKristina BurowPBPaul Berns· per SEC Form D

Co-investorsOROrbiMedSASanofi Ventures

Nanosys develops Quantum Dot technology and materials, providing samples, R&D collaboration, and scaled production for partners building display and other advanced-material products.

Advanced ManufacturingDeep TechHardwareNew MaterialsSemiconductorsMilpitas, US

JHJason Hartlove(Executive Officer, Director)inJCJian Chen(Executive Officer)inRKRussell Kempt(Executive Officer)inNoland Granberry(Executive Officer)in

BoardSteven Goldby(Director)

Board seatKCKeith Crandell· per SEC Form D · $10M raise · filed Mar 2015

Co-investorsPRProspect Venture PartnersSTStructural CapitalTETEL Venture Capital, Inc.VEVenrockCECenterbridge Partners, L.P.FOFortress Investment Group+1 more

RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.

BiotechEmeryville, US

Igor Khandros(Executive Officer, Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investors+N+ND CapitalBLBluebird VenturesSUSutter Hill Ventures

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

ABAlice Bexon(Executive Officer)inCJClifford J. Stocks(Director, Executive Officer)inKDKamal D. Puri(Executive Officer)inCRChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

Board seatSteven Gillis· per SEC Form D

Co-investors3B3B Future Health FundCACanaan PartnersGRGreatPoint VenturesRIRiverVest Venture PartnersBEBering CapitalINIntervest+3 more

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.

BiotechHealthtechMedical DevicesRedwood City, US

IWIrv Weissman(Cofounder, Scientific Advisor, Board Director)RMRavi Majeti(Cofounder, Scientific Advisor, Board Observer)ABAmira Barkal(Principal Founder, Scientific Advisor, Board Director)inRMRoy Maute(Cofounder & Chief Executive Officer)in

BoardJVJacob Vogelstein(Director)

Board seatSteven Gillis· per SEC Form D

Co-investorsCACatalio Capital Management, LPALAlexandriaCACatalio Capital Management

Proniras Corporation is a clinical-stage biotechnology company developing novel small-molecule therapeutics for substance use disorders and specialty central nervous system (CNS) conditions, including treatments for opioid withdrawal and seizure disorders.

BiotechHealthtechSeattle, US

CTCHRISTOPHER TOOMBS(Executive Officer)inLRLINDSAY RAYLE(Executive Officer, Promoter)M. Johnston Erwin(Director)David Schubert(Executive Officer, Promoter)

BoardThong Le(Executive Officer, Director, Promoter)

Board seatSteven Gillis· per SEC Form D

Co-investorsACACCELERATOR LIFE SCIENCE PARTNERSWRWRF Capital

Ramona Optics builds parallelized multi-camera array microscope systems for imaging and analyzing small model organisms and cell cultures in multi-well plates.

BiotechDeep TechHardwareDurham, US

RHRoarke Horstmeyer(Director)inMark Harfouche(Executive Officer, Director)inRobert Horstmeyer(Director)Margaret Aery(Executive Officer)inGregor Horstmeyer(Executive Officer, Director)

Board seatSKSean KendallPWPatrick Weiss· per SEC Form D · $31M raise · filed Mar 2026

Co-investorsTHThe E14 Fund

Rezo maps disease networks to find insights into disease biology for drug discovery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

NKNevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNBNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)GSGeorge Scangos(Co-Founder)Kevan Shokat(Co-Founder)

Board seatGSGeorge Scangos· per SEC Form D · $80.1M raise · filed Aug 2025

Co-investorsANAndreessen HorowitzNONorwest Venture PartnersHAHAWKTAILSRSR One Capital ManagementVAValkyrie Ventures Management, Llc

Rippl delivers evidence-based dementia care through a combination of technology and human support for people living with dementia and their families.

Digital HealthHealthtechSeattle, US

KEKris Engskov(Co-founder & CEO)inRNRobert Nelsen(Co-Founder & Board Chair)Paul Engskov(Executive Officer, Director)

BoardHMHolly Maloney(Director)inIyah Romm(Director)Ryan Watts(Director)

Board seatRNRobert Nelsen· per SEC Form D

Co-investors181843 CapitalCICity LightEQEquitage Ventures, L.L.C.F-F-Prime CapitalGVGV (Google Ventures)GEGeneral Catalyst

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

BiotechHealthtechMedical DevicesSeattle, US

RMRichard Mulligan(Director)inHBHans Bishop(Director)SHSteve Harr(President and Chief Executive Officer)JJJames J. MacDonald(Executive Officer)NHNathan Hardy(Executive Officer)

BoardGVGeoffrey von Maltzahn(Director)in

Board seatRNRobert Nelsen· per SEC Form D

Co-investorsAMAmerican Family VenturesF-F-Prime CapitalFLFlagship PioneeringINInnovating CapitalJDJDRF T1D FundMAManta Ray Ventures+1 more

Semprius was a Durham, NC developer of micro-transfer-printed high-concentration photovoltaic solar modules, spun out of the University of Illinois.

Durham, US

JOHN ROGERS(Executive Officer, Director)JOSEPH CARR(Executive Officer, Director)HELENA YEE(Executive Officer)JACK BARRY(Executive Officer)

BoardGREG WOLF(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsAPApplied VenturesILIllinois Ventures

Seranova is a biotech company that combines REAP autoantibody profiling with clinically linked patient cohorts to identify naturally occurring protective autoantibodies against specific extracellular targets and translate those protective associations into therapeutic hypotheses.

AI & Machine LearningBiotechDeep TechNew Haven, US

ARAaron Ring(Manager)inBeatrice McQueen(Executive Officer)

BoardJim Tananbaum(Manager)

Board seatSabah Oney· per SEC Form D · $10M raise · filed Feb 2024

Co-investorsAXAxial VC

Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.

BiotechWeslake Village, US

Frederick C. Beddingfield III(Executive Officer, Director)THTodd Harris(Director, Executive Officer)inDSDiane Stroehmann(Executive Officer)inPFPaul F. Lizzul(Executive Officer)inRPRic Peterson(Executive Officer)inTimothy K. Andrews(Executive Officer)

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D · $40.5M raise · filed May 2017

San Francisco catalyst company that converted natural gas to ethylene and fuels; acquired by McDermott in 2019.

San Francisco, US

Edward J Dineen(Executive Officer, Director)Jeffrey P. Wood(Executive Officer)

BoardMichel Maloof(Director)Leighton Read(Director)Paula Reynolds(Director)

Board seatCBClinton Bybee· per SEC Form D · $25.7M raise · filed Jan 2016

Co-investorsLULux CapitalPRPresidio VenturesKLKleiner PerkinsSASaudi Aramco Energy Ventures

Boston-area biotech developing gene therapies for genetic causes of pediatric hearing loss.

BiotechCambridge, US

Giampiero De Luca(Director)Jodi A. Cook(Executive Officer, Director)Will McLean(Executive Officer)

Board seatSGSteve Gillis· per SEC Form D

Slingshot Biosciences makes synthetic cell mimics used as standardized reference controls for flow cytometry and cell-based assays.

Emeryville, US

JKJeff Kim(Founder)inAdam Wieschhaus(Director)Ronald J. Silberman(Director)

Board seatCRCorey RitterPWPatrick Weiss· per SEC Form D

Co-investorsANAnterra CapitalNONorthpond Ventures

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.

BiotechDeep TechHealthtechSouth San Francisco, US

KGKenneth Greenberg(Co-Founder, President & CEO)in

Board seatSteven Gillis· per SEC Form D · $125.5M raise · filed Jun 2026

Co-investorsVIVida VenturesLELeaps by BayerFOFoothill VenturesILIllumina VenturesMEMedical Excellence CapitalVIVivo Capital+1 more

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechMedical DevicesWatertown, US

JHJoshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in

BoardAli Satvat(Director)DSDavid Schenkein(Director)in

Board seatKBKristina Burow· per SEC Form D

Co-investorsAIAisling CapitalOROrbiMedCACasdin CapitalFIFidelity InvestmentsGVGV (Google Ventures)RORock Springs Capital+1 more

Unity Biotechnology was a biotechnology company that is no longer operating.

BiotechBrisbane, US

NENathaniel E. David(Executive Officer, Director)inDMDan Marquess(Executive Officer)inKLKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in

Board seatRNRobert NelsenKBKristina Burow· per SEC Form D

Co-investorsAGage1CYCycad Group LLCECEcoR1 CapitalKHKhosla VenturesVEVenrock

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

BCBen Cravatt(Scientific Founder)PBPhil Baran(Scientific Founder)JYJin-Quan Yu(Scientific Founder)

BoardJPJohn Park(Executive Officer)JCJohn Clarke(Executive Officer, Director)in

Board seatKBKristina BurowRHRichard Heyman· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsCACardinal PartnersNENextech InvestSOSoftBank Vision FundALAlexandriaALALTITUDE LIFE SCIENCE VENTURES+4 more

Company producing world's first multi-material 3D printer capable of printing functional features with variable material properties.

Somerville, US

JAJennifer A. Lewis(Executive Officer, Director)

BoardJMJiong Ma(Director)

Board seatCBClinton Bybee· per SEC Form D

Co-investorsBRBraemar Energy VenturesINIn-Q-Tel

Subsea and terrestrial optical transport supplier whose assets, rescued by H.I.G. in 2017, are being bought by Prysmian and Fincantieri.

Allen, US

Keith Henderson(Executive Officer)inLes Barkley(Executive Officer)inPCPaul Colan(Executive Officer)inJHJon Hopper(Executive Officer, Director)inGary Otake(Executive Officer)inHerve Fevrier(Executive Officer)

Board seatCBClinton Bybee· per SEC Form D · $1.5M raise · filed Sep 2016

Co-investorsARAristos Ventures

Accompany was a relationship intelligence and business insights platform that has been acquired by Cisco and integrated into their collaboration products suite.

Enterprise SoftwareSaaS

RMRyan McDonough(Founder)in

Co-investorsCRCRV (Charles River Ventures)VIVista Venture PartnersICICONIQ CapitalIVIVP (Institutional Venture Partners)VEVenrock

Bethesda-based provider of in-home and virtual primary, behavioral and social care for low-income patients with complex needs.

HealthtechBethesda, US

RRRahul Rajkumar(Executive Officer, Director)in

BoardBryan Roberts(Director)Robert Kocher(Director)Stephanie Lovell(Director)Vivian Riefberg(Director)

Co-investorsIVIVP (Institutional Venture Partners)VEVenrockVEVenrock Associates

Ahura Scientific offers portable analytical instruments (under the Thermo Scientific brand) that use XRF, NIR, Raman, and FTIR technologies for rapid chemical identification and material verification in field environments.

Advanced ManufacturingDeep TechHardware

Co-investorsCACastile VenturesFUFuse Capital

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsSRSR One Capital Management

Aledade is an accountable care organization (ACO) partner that works with primary care organizations to improve patient outcomes and healthcare quality.

Enterprise SoftwareHealthtechBethesda, US

BSBijan Salehizadeh(Co-founder)inFMFarzad Mostashari(Chief Executive Officer and Co-Founder)inMKMat Kendall(President and Co-Founder)in

BoardRKRobert Kocher(Director)in

Co-investorsACActivate Venture PartnersECEcho Health VenturesGVGV (Google Ventures)INIntrepid Growth PartnersIVIVP (Institutional Venture Partners)LILightspeed Venture Partners+12 more

Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.

BiotechDeep TechLongevityBay Area, US

Richard Murray(CEO and Founder)Shinya Yamanaka(Chief Scientific Advisor and Founder)HBHal Barron(Founder)inRKRichard Klausner(Founder)

Co-investors8V8VCGEGeneral Catalyst

Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.

Co-investorsBOBoulder Ventures

Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.

BiotechHealthtechMedical DevicesSouth San Francisco, US

KDKen Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)

BoardValentin Barsan(Director)Sean Parker(Director)

Co-investorsHIHitachi VenturesKLKleiner PerkinsOUOUP (Osage University Partners)SOSoftBank Vision FundWEWestlake Village BioPartners

Co-investorsALAlta PartnersDCDC Investment PartnersLOLongwood FundNENextech InvestPAPathway to CuresATAtlas Venture+6 more

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications.

BiotechDeep TechHealthtechMedical Devices

DMDr Mark Kotter(Founder)POPrzemek Obloj(CEO)inEPEmma Pepperellin

Co-investorsFOForesite CapitalBLBlueYard CapitalDYDynamk CapitalGOGood AI CapitalHAHAWKTAILMEMetaplanet+2 more

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.

BiotechLongevityMedical DevicesCambridge, US

DMDavid Meek(Chief Executive Officer)inBRBrian Riley(President & Chief Technical Officer)inJLJoanne Lager(Chief Medical Officer)inWDWendy DiCicco(Chief Financial Officer)inACAdrian Chaisson(Chief of Staff)inJCJason Cole(Executive Officer)

Co-investorsEAEaston CapitalRARA CapitalSASanofi Ventures

Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.

ZHZhi Hong(Founder)in

Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

TPTimothy Pearson(CEO)ABAsh Bahl(CSO)inJHJenny Horsfield(CBO)inSMStuart McIntosh(CMO)inDSDavid Sutherland(VP Finance & Controller)

Co-investorsB B Capital GroupB4B4 CapitalCACambridge Innovation CapitalLILightstone Ventures

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)inTTTodd T. Foley(Director)inVincent Miles(Director)AKAnsbert K. Gadicke(Director)in

Co-investorsHEHEALTHCARE ROYALTY PARTNERSSOSofinnova VenturesABAbingworthMPMPM BioImpact

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

MKMark Keating, MD(Co-founder)KNKotaro Nakanishi, PhD(Co-founder)YTYukihide Tomari, PhD(Co-founder)PZPhillip Zamore, PhD(Co-founder)

Co-investorsANAN Venture PartnersSOSofinnova VenturesCACasdin CapitalFIFidelity InvestmentsINInvusRORock Springs Capital

Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.

BiotechSeattle, US

DWDoug Williams(Executive Officer, Director)in

BoardNANoubar Afeyan(Director)inSteven Gillis(Director)Eric Lander(Director)

Co-investorsECEcoR1 CapitalFLFlagship Pioneering

Countable Labs (formerly Enumerix) develops Countable PCR, a DNA quantification technology that provides absolute target counts at single-molecule resolution as an alternative to qPCR, digital PCR, and NGS.

BiotechDeep TechHealthtechMedical DevicesPalo Alto, US

SFStephen Fodor(Co-Founder & Board Director)ACAri Chaney(Co-Founder & Board Director)inCFChristina Fan(Co-founder + CTO)inGPGiovanna Prout(Chief Executive Officer)in

Co-investorsF-F-Prime CapitalPRPrimer Ventures

Hong Kong-listed (HKEX: 2616) Chinese biopharmaceutical company developing oncology, immunology and inflammation therapies.

Co-investorsGIGIC

Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.

ZWZach Weinberg(Founder)in

Co-investorsALAlleyCorpDNDNA CapitalF-F-Prime CapitalGVGV (Google Ventures)SHShine CapitalALAlley Robotics Ventures+1 more

deCODE analyzes and interprets the human genome to identify genetic risk factors for common diseases including cardiovascular disease and cancer.

AI & Machine LearningBiotechDeep TechReykjavik, IS

Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.

CleantechClimate TechDeep TechNew Materials

CNChiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in

Co-investorsPAPacific Channel3E3E Bioventures CapitalECEcoR1 CapitalGEGeneral CatalystLELeaps by BayerMAMaverick Ventures+2 more

Dispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

BiotechDeep TechMedical Devices

LJLex Johnson(Co-Founder and Chief Platform Officer)inRLRay Liu(Co-founder and Head of Synthetic Biology)JMJeff Marrazzo(Founder)inSOSabah Oney(Chief Executive Officer)in

Encoded develops gene therapies for neurological disorders through an integrated platform approach.

Biotech

STStephanie Tagliatela(Founder)in

Co-investorsBIBioBritGVGV (Google Ventures)ILIllumina VenturesMEMenlo VenturesSOSoftBank Vision FundVEVenrock+1 more

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsDEDecheng CapitalALAlexandriaDEDeerfield Management CompanyGVGV (Google Ventures)NANan Fung Life SciencesNONorthpond Ventures

Countable Labs (formerly Enumerix) develops a digital PCR platform that performs genetic analysis with higher sensitivity, precision, and dynamic range than legacy PCR methods.

AI & Machine LearningBiotechDeep TechMedical Devices

Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.

BiotechMedical DevicesSan Diego, US

PTPam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)PTPam Taub, M.D., FACC(Co-founder)

Co-investorsBLBluebird VenturesBRBroadview VenturesLOLongitude CapitalADAdams Street PartnersVEVertex VenturesVEVertex Ventures HC

EQRx was a Cambridge, MA biopharma that aimed to sell lower-priced novel drugs; it was acquired by Revolution Medicines in 2023.

Co-investorsANAndreessen HorowitzARArboretum VenturesGVGV (Google Ventures)BABain Capital

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsFOForbionVEVersant VenturesANAndreessen HorowitzGVGV (Google Ventures)

GRAIL develops a blood-based multi-cancer early detection test called Galleri that uses next-generation sequencing and machine learning to screen for multiple cancer types before symptoms appear.

BiotechDigital HealthHealthtechMedical DevicesMenlo Park, US

Co-investorsBEBezos Expeditions

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

LJLeslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)SMSeiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)SGSteven Gillis(Director)in

Co-investors8V8VCTATaiho Ventures, LLCTATakeda Ventures

Comofi Medtech develops healthcare technology, including an AI/AR-based surgical intervention platform for surgical procedures and an NT-Mask, aimed at improving patient outcomes and the safety and efficiency of healthcare practitioners.

AI & Machine LearningHealthtechMedical Devices

Co-investorsJIJITO Angel NetworkCICIIE.COIIIIMA VenturesABAbstract VenturesGEGeneral CatalystLILightspeed Venture Partners

Butterfly Learnings provides developmental and behavioral therapy for children with autism, including speech and behavior support delivered by senior and behavior therapists.

Digital HealthHealthtechWellness & FitnessMumbai, IN

Co-investorsIIIIMA VenturesINInsitorABAbstract VenturesGEGeneral CatalystLILightspeed Venture Partners

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsARArkin CapitalJEJeito CapitalMOMonograph Capital PartnersALAlpha Wave GlobalVIViking Global Investors

HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.

BiotechMedical Devices

JAJulio Aguirre-Ghiso, Ph.D.(Co-Founder)

Co-investorsMAMagnetic VenturesRARaptor Group6 6 Dimensions CapitalHEHercules Capital, Inc.HIHillhouse Capital

Homeward provides cash offers for home purchases, allowing buyers to make competitive offers without financing contingencies while enabling real estate agents to maintain full commissions.

FintechPropTechAustin, US

Jeff Diehl(Director)Jeffrey Crowe(Director)Srini Palamarthy(Executive Officer)Ben Rubenstein(Director)

BoardTHTim Heyl(Executive Officer, Director)inKSKrishna Srinivasan(Director)in

Co-investorsBRBreyer CapitalEREra VenturesHAHarmony PartnersJAJavelin Venture PartnersLILiveOak VenturesNONorwest Venture Partners+3 more

Homeward Health provides in-home and virtual primary care and care coordination services for Medicare Advantage patients, helping with appointment scheduling, health advocacy, insurance navigation, and access to community resources.

Digital HealthHealthtech

Co-investorsHUHuman Capital

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)ATArthur Tzianabos(Executive Officer, Director)KPKush Parmar(Director)inRichard Gregory(Director)

Co-investors5A5AM VenturesOUOUP (Osage University Partners)ALAlexandriaDEDeerfield Management CompanyHBHBM Healthcare InvestmentsMAMaverick Ventures+4 more

Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.

Co-investorsF-F-Prime CapitalVEVenrock6 6 Dimensions CapitalBLBlue Pool CapitalEIEight Roads VenturesPIPing An

Scalable, high throughput DNA sequencing platforms.

Co-investorsARArtis VenturesHEHemisphere Ventures LLCHEHeran PartnersSPSPRINGROCK VENTURESVEVenrockGEGenesys Capital

ImmusanT works on scientific research into the mechanisms of celiac disease, collaborating with investigators from academic and medical research institutions.

BiotechHealthtechCambridge, US

LWLeslie Williams(Executive Officer, Director)Thomas Daniel(Director)Steven Gillis(Director)Thomas Koestler(Director)

BoardCeclia Gonzalo(Director)Kevin Ferro(Director)

Co-investorsVAVatera Healthcare Partners

Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.

BiotechHealthtechMedical Devices

JNJoseph Nolanin

Co-investorsAIAIFJDJDRF T1D FundDEDeerfield Management CompanyGOGoldman SachsSASamsung Ventures

Seattle-based cancer immunotherapy company developing CAR-T and TCR cell therapies; acquired by Celgene, now part of Bristol-Myers Squibb.

Co-investorsBEBezos Expeditions

Just - Evotec Biologics is a contract development and manufacturing organization (CDMO) providing antibody discovery, process development, and cGMP manufacturing services for antibodies, next-generation biologics, and biosimilars.

Advanced ManufacturingBiotechHealthtechSeattle, US

A biopharmaceutical company developing CAR-T cell therapies for cancer treatment.

BiotechHealthtechMedical DevicesShanghai, CN

Co-investorsACAcorn Pacific VenturesYUYuanBio Venture Capital

Karuna Therapeutics is a Boston neuroscience biopharma behind muscarinic drug KarXT, acquired by Bristol Myers Squibb in 2024.

Co-investorsSOSofinnova Ventures

Kisbee Therapeutics is a Watertown, Massachusetts biotech/healthtech company founded in 2019 and backed by ARCH Venture Partners.

KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DPDAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)

BoardALALAN L. CRANE(Director)

Co-investorsALAlpha Wave GlobalFLFlagship PioneeringLALAVLGLG Technology VenturesLILilly Asia VenturesBABaillie Gifford+1 more

Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.

Co-investorsAIAisling CapitalPRProspect Venture PartnersSCSchooner CapitalALALTITUDE LIFE SCIENCE VENTURESFOFoley VenturesINInvus

LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.

AI & Machine LearningBiotechDeep TechCambridge, US

GLGregory L. Verdine(Executive Officer, Director)GVGregory Verdine, Ph.D.

BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)

Co-investorsGVGV (Google Ventures)BLBlue Pool CapitalFIFidelity Investments

Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.

BiotechDeep TechHealthtech

Co-investors+N+ND CapitalILIllumina VenturesLOLongwall Venture Partners LLPM M VenturesOMOMX Ventures

Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.

BiotechDeep TechMedical DevicesCambridge, GB

Co-investorsILIllumina VenturesPEPerscitus LLP

San Diego, US

Bob Kain(Executive Officer, Director)inDBDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)

Co-investorsBABain Capital VenturesF-F-Prime CapitalILIllumina VenturesOSOsage University Partners

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHTHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsFOForesite CapitalVEvenBio Partners8V8VCAXAxial VC

Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsCRCross Creek AdvisorsPFPfizer Venture InvestmentsSISignet Healthcare PartnersSOSofinnova Ventures

A manufacturing company focused on domestic production of robotics, aiming to build large-scale factories and apply AI in manufacturing.

Advanced ManufacturingAI & Machine LearningRobotics

Co-investorsSCScribble VenturesTHThe Westly GroupCOCollaborative FundEXExor Ventures

Matter is a read-later app for iPhone, iPad, and web that saves articles, newsletters, threads, PDFs, and video/podcast content with parsing and search capabilities.

ConsumerMedia & EntertainmentSaaSSan Francisco, US

BSBen Springwater(Founder)inRMRobert Mackenzie(Founder)in

Co-investorsADAdapt VenturesOUOutliers VCY Y CombinatorANAndreessen HorowitzCOCollaborative FundEXExor Ventures+4 more

Matter develops a consumer iOS app that helps users track positive emotions and brain activity to improve subjective well-being.

AI & Machine LearningConsumerHealthtechMental HealthWellness & Fitness

ABAxel Bouchon(Founder)inBen Goldhirsh(Co-founder)inCSChris Shiflett(Co-founder)in

Co-investorsCOCollaborative FundEXExor VenturesPOPolaris Partners

Mirador provides digital lending platform software for financial institutions, credit unions, and banks to streamline online loan applications.

Cloud ComputingEnterprise SoftwareFintechSaaS

Co-investorsNYNycaNYNyca PartnersCOCore Venture CapitalFIFidelity InvestmentsINInvusOROrbiMed+3 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

MDMark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)CKCalvin Kuo(Scientific Co-Founder)KFKatie Fanning(President & Chief Executive Officer)in

Co-investorsJDJDRF T1D FundMRMRL Ventures FundONOno Venture Investment, Inc.PFPfizer Venture InvestmentsSOSofinnova PartnersALAlexandria+4 more

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.

AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US

DGDaniel Getts, Ph.D.(Chief Executive Officer, Cofounder, Board Director)

Co-investors8V8VCHAHatteras Venture PartnersNENewpath Partners

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical DevicesBoston, US

LGLuke Gilbert, PhD(Founder)Keith Joung, MD, PhD(Founder)DLDavid Liu, PhD(Founder)ALAngelo Lombardo, PhD(Founder)Luigi Naldini, MD, PhD(Founder)JWJonathan Weissman, PhD

Co-investorsATAtlas VentureNENewpath PartnersDCDCVC (Data Collective)F-F-Prime CapitalGVGV (Google Ventures)5A5AM Ventures+2 more

San Diego DNA sequencing company behind the Sequencing by Binding short-read platform; acquired by Pacific Biosciences in 2021.

BiotechSan Diego, US

David S. Mullarkey(Executive Officer, Director)AOArnold Oliphant(Executive Officer)inKSKen Song, M.D., Ph.D.(Executive Officer, Director)Kelly Perez(Executive Officer)John Murphy, Ph.D.(Executive Officer)Millard Y Chan(Chief Operating Officer, Secretary and Director)

Co-investorsDCDCVC (Data Collective)DEDecheng CapitalLALam CapitalALALTITUDE LIFE SCIENCE VENTURESDODomain AssociatesHIHillhouse Capital+1 more

Singapore A*STAR spin-off building automated nucleic acid extraction and silicon-photonics point-of-care molecular diagnostics.

ONI develops the Nanoimager, an automated super-resolution imaging system.

BiotechDeep TechHardwareMedical DevicesOxford, GB

Co-investorsARArtis VenturesFUFuture Planet CapitalOXOxford Technology ManagementVEVertical Venture PartnersAXAxon VenturesCACasdin Capital+5 more

A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.

BiotechHealthtechMedical Devices

Co-investorsANAndreessen HorowitzIGiGlobe PartnersAGAgent CapitalNENewpath PartnersREREDMILE

Paradigm Health is an Indiana-based hospice and palliative care provider offering community-based, holistic care to patients and support for their families and caregivers.

Digital HealthHealthtechWellness & Fitness

JJJeff Jarecki(Founder & Chairman)in

Co-investorsHAHavencrest Capital ManagementGEGeneral CatalystGVGV (Google Ventures)LULux CapitalMUMubadala Capital

Paratus Sciences is a drug discovery company that uses AI-powered methods to identify first-in-class medicines by studying evolutionary traits, targeting serious diseases where current therapies are inadequate.

AI & Machine LearningBiotechDeep TechUnited States, US

Co-investorsCLClavystBioECEcoR1 CapitalLELeaps by Bayer

Moonwalk Biosciences is a life sciences company operating in the biotech sector.

AI & Machine LearningBiotechDeep TechHealthtechSouth San Francisco, US

AJArash Jamshidi(Co-Founder, President & CTO)inAAAlex Aravanis(Co-Founder & CEO)in

Co-investorsALAlpha Wave GlobalKHKhosla Ventures

Prometheus Fuels develops systems that convert intermittent renewable energy into liquid fuels for remote electrification.

Advanced ManufacturingCleantechClimate TechDeep TechEnergySanta Cruz, US

RMRob McGinnis(Founder/CEO)in

Co-investorsBMBMW i VenturesEMEmles Venture PartnersEXExpaMAMaersk GrowthMEMetaplanetY Y Combinator+3 more

Protillion Biosciences develops platform technology for antibody engineering and drug discovery.

AI & Machine LearningBiotechDeep TechCarlsbad, US

CLCurtis Layton(CEO/Co-Founder)inDWDavid Walt(Co-Founder)inWGWill Greenleaf(Co-Founder)inRHRobert Hollingsworth(Chief Scientific Officer)in

BoardSKSean Kendall(Director)inMFMalek Faham(Director)in

Co-investorsILIllumina Ventures